CNA Financial Corporation
NYSE:CNAInsurance - Property & Casualty
-$0.24 today
- Market cap
- $13.12B
- Beta
- 0.32
- P/E (TTM)
- 9.2
- EPS (TTM)
- $4.91
- Dividend yield
- 8.57%
Volume 0.50M
Average 0.48M
CNA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CNA Financial CorporationNYSE: CNA
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development remains negative
Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CNA compares with its peers on the latest reported figures
- CNA's LTM Sep 2026 research & development of $0 is the highest of the 11 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for CNA, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CNA) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for CNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.55B | 11.89B | 13.13B | 14B | 14.71B |
| Cost of Revenue | 7.81B | 8.14B | 8.71B | 9.54B | 10.19B |
| Gross Profit | 3.73B | 3.75B | 4.41B | 4.46B | 4.52B |
| Gross Margin | 32.3% | 31.5% | 33.6% | 31.9% | 30.7% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 2.27B | 2.93B | 2.9B | 3.25B | 2.9B |
| Depreciation & Amortization | 54M | 51M | 73M | 67M | 70M |
| EBITDA | 1.63B | 977M | 1.72B | 1.41B | 1.83B |
| EBITDA Margin | 14.1% | 8.2% | 13.1% | 10.1% | 12.4% |
| Operating Income | 1.46B | 814M | 1.52B | 1.21B | 1.62B |
| Operating Margin | 12.7% | 6.8% | 11.6% | 8.7% | 11.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 113M | 112M | 127M | 133M | 135M |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 1.46B | 814M | 1.52B | 1.21B | 1.62B |
| Pre-Tax Margin | 12.7% | 6.8% | 11.6% | 8.7% | 11.0% |
| Income Tax Expense | 278M | 132M | 313M | 252M | 342M |
| Net Income | 1.18B | 682M | 1.21B | 959M | 1.28B |
| Net Margin | 10.3% | 5.7% | 9.2% | 6.9% | 8.7% |
| EPS (Basic) | 4.42 | 2.51 | 4.44 | 3.53 | 4.71 |
| EPS (Diluted) | 4.41 | 2.50 | 4.43 | 3.52 | 4.69 |
| Weighted Avg Shares | 271.8M | 271.6M | 271.3M | 271.3M | 271.1M |
| Weighted Avg Shares (Diluted) | 272.8M | 272.5M | 272.2M | 272.7M | 272.3M |
CNA Financial Corporation
NYSE:CNA
Intrinsic Alpha fair value
Locked
Current Price
$48.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.